WCLC2020: Pre-operative treatment with atezolizumab in untreated stage IB-IIIB resectable NSCLC
In this MEDtalk Jay M. Lee, M.D. Chief, Division of Thoracic Surgery UCLA Health, present data for pre-operative treatment with atezolizumab of patients without EGFR/ALK mutations who underwent surgery. The study shows that the major pathological response rate was 20% and the pathological complete response rate was 7%. Neoadjuvant atezolizumab in resectable stage IB-IIIB NSCLC was well tolerated, with no safety concerns.
